racem.-2,3-dibenzyl-succinic acid | 5692-95-5

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物 - 二苄基丁烷木脂素
• 英文名称: racem.-2,3-dibenzyl-succinic acid
• 英文别名: racem.-2,3-Dibenzyl-bernsteinsaeure；D,L-2,3-Dibenzyl-bernsteinsaeure；(2S,3S)-2,3-dibenzylbutanedioic acid
• CAS: 5692-95-5；119516-57-3；119516-58-4；120016-76-4；123295-57-8；123295-60-3
• 化学式: C₁₈H₁₈O₄
• 分子量: 298.339
• InChiKey: UUTKSMWBUAJELT-HOTGVXAUSA-N

物化性质

• 沸点：
  425.3±40.0 °C(Predicted)
• 密度：
  1.248±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2917399090

反应信息

• 作为反应物：
  描述：

  racem.-2,3-dibenzyl-succinic acid 在 乙醚 、 硫酸 作用下， 生成 6,11-bis-(5-bromo-2-methoxy-phenyl)-6,11,11a,12-tetrahydro-5aH-naphthacen-5-one
  参考文献：
  名称：

  EXPERIMENTS IN THE ARYL NAPHTHACENE SERIES. PART III

  摘要：

  DOI：

  10.1021/jo01191a010
• 作为产物：
  描述：

  racem.-2,3-dibenzyl-succinic acid-anhydride 在 sodium carbonate 作用下， 生成 racem.-2,3-dibenzyl-succinic acid
  参考文献：
  名称：

  Cordier, Annales de Chimie (Cachan, France), 1931, vol. <10> 15, p. 228,298, 301

  摘要：

  DOI：

文献信息

• Metallo-beta-lactamase inhibitors
  申请人：Chikauchi Ken

  公开号：US20080090825A1

  公开（公告）日：2008-04-17

  A new metallo-β-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of β-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-β-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of β-lactam antibiotics against metallo-β-lactamase producing bacteria by combining the compound of the general formula (I) with β-lactam antibiotics.

  一种新的金属β-内酰胺酶抑制剂，作为一种药物用于抑制β-内酰胺类抗生素的失活并恢复抗菌活性。具有一般式（I）的马来酸衍生物具有金属β-内酰胺酶抑制活性。通过将一般式（I）的化合物与β-内酰胺类抗生素结合，可以恢复β-内酰胺酶产生细菌对β-内酰胺类抗生素的抗菌活性。
• Double asymmetric hydrogenation of conjugated dienes catalysed by ruthenium binap complexes
  作者：Hitoshi Muramatsu、Hiroyuki Kawano、Youichi Ishii、Masahiko Saburi、Yasuzo Uchida

  DOI：10.1039/c39890000769

  日期：——

  Buta-1,3-diene-2,3-dicarboxylic acid is smoothly hydrogenated in the presence of a ruthenium–(R)-binap complex as a catalyst via two consecutive 1,2-hydrogen additions, giving rise to (S,S)-2,3-dimethylsuccinic acid with 98% diastereoisomeric excess and 96% enantiomeric excess.

  丁-1,3-二烯-2,3-二羧酸被平稳地在钌（的存在下氢化- [R）-BINAP络合物作为催化剂通过两个连续的1,2-氢的添加，从而产生（小号，小号）-2,3-二甲基琥珀酸，其非对映异构体过量为98％，对映异构体过量为96％。
• The Role of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in the Management of Diabetic Complications
  作者：Toomas Podar、Jaakko Tuomilehto

  DOI：10.2165/00003495-200262140-00001

  日期：——

  Evidence suggests that ACE inhibitors can be advantageous for prevention and halting progression of both micro- and macrovascular complications in patients with diabetes mellitus. ACE inhibitors are useful antihypertensive agents in both type 1 and type 2 diabetes; however, ACE inhibitor therapy often needs to be supplemented with calcium channel antagonists, β-blockers or diuretics to achieve good blood pressure control. ACE inhibitors are also indicated in non- hypertensive patients with type 1 and type 2 diabetes who have micro- or macroalbuminuria. The effect of ACE inhibitors in halting the development and progression of retinopathy and, potentially, neuropathy needs further proof in large-scale studies. More recently, angiotensin II receptor antagonists are emerging as drugs with the potential to be successfully included in the management of diabetic complications, especially when ACE inhibitors are not suitable because of adverse effects.

  证据表明，ACE抑制剂在预防和阻止糖尿病患者微血管和大血管并发症的进展方面是有利的。ACE抑制剂是1型和2型糖尿病患者有效的降压药；然而，ACE抑制剂疗法通常需要与钙通道拮抗剂、β-阻滞剂或利尿剂联合使用，以实现良好的血压控制。在有微或大尿蛋白症的1型和2型糖尿病非高血压患者中，也适合使用ACE抑制剂。ACE抑制剂在阻止视网膜病变及潜在神经病变的发展和进展方面的效果，需要在大规模研究中进一步验证。最近，血管紧张素II受体拮抗剂作为一种药物逐渐受到关注，具有成功纳入糖尿病并发症管理的潜力，尤其是在因不良反应而不适合使用ACE抑制剂的情况下。
• METALLO-BETA-LACTAMASE INHIBITORS
  申请人：Chikauchi Ken

  公开号：US20120071457A1

  公开（公告）日：2012-03-22

  A new metallo-β-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of β-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-β-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of β-lactam antibiotics against metallo-β-lactamase producing bacteria by combining the compound of the general formula (I) with β-lactam antibiotics.

  本发明揭示了一种新型金属β-内酰胺酶抑制剂，可作为药物用于抑制β-内酰胺类抗生素的失活并恢复其抗菌活性。具有通式（I）的马来酸衍生物具有金属β-内酰胺酶抑制活性。将通式（I）化合物与β-内酰胺类抗生素结合，可以恢复β-内酰胺酶产生的细菌对β-内酰胺类抗生素的抗菌活性。
• METALLO-B-LACTAMASE INHIBITORS
  申请人：MEIJI SEIKA KAISHA, LTD.

  公开号：US20160151322A1

  公开（公告）日：2016-06-02

  A new metallo-β-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of β-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-β-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of β-lactam antibiotics against metallo-β-lactamase producing bacteria by combining the compound of the general formula (I) with β-lactam antibiotics.

  揭示了一种新的金属β-内酰胺酶抑制剂，可作为药物用于抑制β-内酰胺类抗生素的失活并恢复其抗菌活性。具有通式(I)的马来酸衍生物具有金属β-内酰胺酶抑制活性。通过将通式(I)的化合物与β-内酰胺类抗生素结合，可以恢复β-内酰胺酶产生的细菌对β-内酰胺类抗生素的抗菌活性。